AU2021369508B2 - Pharmaceutical compositions and methods of using the same for treating cancer - Google Patents

Pharmaceutical compositions and methods of using the same for treating cancer

Info

Publication number
AU2021369508B2
AU2021369508B2 AU2021369508A AU2021369508A AU2021369508B2 AU 2021369508 B2 AU2021369508 B2 AU 2021369508B2 AU 2021369508 A AU2021369508 A AU 2021369508A AU 2021369508 A AU2021369508 A AU 2021369508A AU 2021369508 B2 AU2021369508 B2 AU 2021369508B2
Authority
AU
Australia
Prior art keywords
dosage form
oral dosage
subject
venetoclax
solid oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021369508A
Other languages
English (en)
Other versions
AU2021369508A1 (en
Inventor
Kim-Hien DAO
Harold Keer
Aram Oganesian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of AU2021369508A1 publication Critical patent/AU2021369508A1/en
Assigned to TAIHO PHARMACEUTICAL CO., LTD. reassignment TAIHO PHARMACEUTICAL CO., LTD. Request for Assignment Assignors: OTSUKA PHARMACEUTICAL CO., LTD.
Application granted granted Critical
Publication of AU2021369508B2 publication Critical patent/AU2021369508B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021369508A 2020-10-29 2021-10-27 Pharmaceutical compositions and methods of using the same for treating cancer Active AU2021369508B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063107010P 2020-10-29 2020-10-29
US63/107,010 2020-10-29
PCT/US2021/056809 WO2022093930A1 (en) 2020-10-29 2021-10-27 Pharmaceutical compositions and methods of using the same for treating cancer

Publications (2)

Publication Number Publication Date
AU2021369508A1 AU2021369508A1 (en) 2023-03-02
AU2021369508B2 true AU2021369508B2 (en) 2026-07-09

Family

ID=81384423

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021369508A Active AU2021369508B2 (en) 2020-10-29 2021-10-27 Pharmaceutical compositions and methods of using the same for treating cancer

Country Status (10)

Country Link
US (1) US12697347B2 (enExample)
EP (1) EP4237094A4 (enExample)
JP (2) JP2023548303A (enExample)
KR (1) KR20230097034A (enExample)
CN (2) CN122182592A (enExample)
AU (1) AU2021369508B2 (enExample)
CA (1) CA3188316A1 (enExample)
MX (1) MX2023003305A (enExample)
TW (1) TW202227096A (enExample)
WO (1) WO2022093930A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023548303A (ja) 2020-10-29 2023-11-16 大塚製薬株式会社 癌を処置する為の医薬組成物及びその使用方法
AU2024265282A1 (en) * 2023-05-02 2025-12-18 Taiho Pharmaceutical Co., Ltd. Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085848A1 (en) * 2018-09-19 2020-03-19 Otsuka Pharmaceutical Co., Ltd. Low dose combination cda substrate drug/cedazuridine with extended administration

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2708264C (en) 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
US9834576B2 (en) 2013-10-29 2017-12-05 Otsuka Pharmaceutical Co., Ltd. Synthetic route to 2′-deoxy-2′,2′-difluorotetrahydrouridines
US10683552B2 (en) 2014-11-25 2020-06-16 Presidents And Fellows Of Harvard College Clonal haematopoiesis
SG11202108523UA (en) * 2019-03-25 2021-09-29 Otsuka Pharma Co Ltd Antitumor composition
MX2022005811A (es) 2019-11-13 2022-06-08 Taiho Pharmaceutical Co Ltd Sal novedosa de compuesto de terfenilo.
WO2021113688A1 (en) 2019-12-05 2021-06-10 Sumitomo Dainippon Pharma Oncology, Inc. Combination therapies for treatment of myelodysplastic syndrome
EP4090335A1 (en) 2020-01-17 2022-11-23 Novartis AG Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
LT4069254T (lt) 2020-02-25 2024-10-10 Otsuka Pharmaceutical Co., Ltd. Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną
JP2023548303A (ja) 2020-10-29 2023-11-16 大塚製薬株式会社 癌を処置する為の医薬組成物及びその使用方法
JP2024521824A (ja) 2021-05-27 2024-06-04 ヴァンダービルト ユニヴァーシティ マクロライド化合物
MX2024003537A (es) 2021-09-21 2024-05-03 Otsuka Pharma Co Ltd Metodos de tratamiento de los sindrome mielodisplasico con decitabina y cedazuridina.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085848A1 (en) * 2018-09-19 2020-03-19 Otsuka Pharmaceutical Co., Ltd. Low dose combination cda substrate drug/cedazuridine with extended administration

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ABBVIE: "Prescribing information", PRESCRIBING INFORMATION, 30 April 2019 (2019-04-30), pages 1 - 49, XP009537467 *
BRIAN A. JONAS: "How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia", LEUKEMIA, vol. 33, no. 12, 18 October 2019, pages 2795-2804. *
GU XIAORONG ET AL: "Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network", LEUKEMIA, vol. 35, no. 4, 7 August 2020, pages 1023 - 1036, DOI: 10.1038/S41375-020-1003-X. *
GUILLERMO GARCIA-MANERO: "Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study", BLOOD, 6 August 2020, DOI: https://doi.org/10.1182/blood.2019004143. *

Also Published As

Publication number Publication date
JP2023548303A (ja) 2023-11-16
CN116018145A (zh) 2023-04-25
TW202227096A (zh) 2022-07-16
KR20230097034A (ko) 2023-06-30
CA3188316A1 (en) 2022-05-05
US20230405037A1 (en) 2023-12-21
US12697347B2 (en) 2026-08-04
WO2022093930A1 (en) 2022-05-05
JP2026083415A (ja) 2026-05-19
MX2023003305A (es) 2023-04-13
AU2021369508A1 (en) 2023-03-02
CN122182592A (zh) 2026-06-12
EP4237094A4 (en) 2024-07-10
EP4237094A1 (en) 2023-09-06

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TAIHO PHARMACEUTICAL CO., LTD.

Free format text: FORMER APPLICANT(S): OTSUKA PHARMACEUTICAL CO., LTD.